Cytovance Biologics
Cytovance Biologics is a US-based contract development and manufacturing organization (CDMO) focused on large-molecule biologics. The company provides end-to-end services spanning strain and cell-line development, upstream and downstream process development, analytical development (including mass spectrometry), formulation development, and cGMP clinical-to-commercial manufacturing. Cytovance reports experience supporting hundreds of clinical programs, multiple FDA inspections, and global customers from its Oklahoma City site.
Industries
Nr. of Employees
large (251-1000)
Cytovance Biologics
Oklahoma City, Oklahoma, United States, North America
Products
Optimized pDNA manufacturing platform
An optimized platform process for plasmid DNA production on single-use systems designed to balance quality and cost for clinical and commercial pDNA supply.
Optimized pDNA manufacturing platform
An optimized platform process for plasmid DNA production on single-use systems designed to balance quality and cost for clinical and commercial pDNA supply.
Services
Integrated services from DNA/strain and cell-line development through process development, analytical development, formulation, and cGMP manufacturing for clinical and commercial supply.
Strain development, upstream fermentation process development (batch and fed-batch), and scale-up for microbial-expressed biologics.
Cell line generation and optimization, bioreactor process development for CHO and other mammalian hosts, and rapid scale-up strategies.
Development of purification trains, aggregate removal steps, impurity identification and mitigation strategies for biologics.
Analytical method development, qualification, and routine testing services including mass spectrometry and assay transfers.
In-house formulation development to support drug product stability and downstream processing requirements.
Integrated services from DNA/strain and cell-line development through process development, analytical development, formulation, and cGMP manufacturing for clinical and commercial supply.
Strain development, upstream fermentation process development (batch and fed-batch), and scale-up for microbial-expressed biologics.
Cell line generation and optimization, bioreactor process development for CHO and other mammalian hosts, and rapid scale-up strategies.
Development of purification trains, aggregate removal steps, impurity identification and mitigation strategies for biologics.
Analytical method development, qualification, and routine testing services including mass spectrometry and assay transfers.
In-house formulation development to support drug product stability and downstream processing requirements.
Expertise Areas
- Large-molecule CDMO services
- Microbial biomanufacturing and fermentation
- Mammalian cell line development and CHO processes
- Plasmid DNA (pDNA) manufacturing
Key Technologies
- Fed-batch fermentation
- CHO cell expression systems
- Plasmid DNA single-use manufacturing platforms
- Mass spectrometry for biologics characterization
News & Updates
In-person industry event participation scheduled for October 28–30, 2025.
In-person participation at BioProcess International East, September 15-18, 2025.
Company reflection on two decades of growth and service from Oklahoma City.
Article describing the role of AI in biomanufacturing and collaborative research with the University of Oklahoma.
Announcement of the addition of formulation development services to the company's service offerings.
Series of appearances on Outsourced Pharma to discuss capacity, microbial and mammalian capabilities, and scale-up success.
In-person industry event participation scheduled for October 28–30, 2025.
In-person participation at BioProcess International East, September 15-18, 2025.
Company reflection on two decades of growth and service from Oklahoma City.
Article describing the role of AI in biomanufacturing and collaborative research with the University of Oklahoma.
Announcement of the addition of formulation development services to the company's service offerings.
Series of appearances on Outsourced Pharma to discuss capacity, microbial and mammalian capabilities, and scale-up success.